JP5957517B2 - 結膜弛緩症治療用の点眼薬 - Google Patents
結膜弛緩症治療用の点眼薬 Download PDFInfo
- Publication number
- JP5957517B2 JP5957517B2 JP2014508913A JP2014508913A JP5957517B2 JP 5957517 B2 JP5957517 B2 JP 5957517B2 JP 2014508913 A JP2014508913 A JP 2014508913A JP 2014508913 A JP2014508913 A JP 2014508913A JP 5957517 B2 JP5957517 B2 JP 5957517B2
- Authority
- JP
- Japan
- Prior art keywords
- eye drop
- drop according
- eye
- solution
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003889 eye drop Substances 0.000 title claims description 48
- 229940012356 eye drops Drugs 0.000 title claims description 12
- 201000000009 conjunctivochalasis Diseases 0.000 title description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 238000012148 non-surgical treatment Methods 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940125702 ophthalmic agent Drugs 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
グリセロール 2.5g、
ヒアルロン酸ナトリウム 0.1g、
水 100mlとするに充分な量、
溶液は、pH7.2に中和された。
グリセロール 2.5g、
ヒアルロン酸ナトリウム 0.015g、
カルボマー481 0.015g、
水 100mlとするに充分な量、
溶液は、pH7に調整された。
グリセロール 2.5g、
ジクロフェナクナトリウム 0.1g、
水 100mlとするに充分な量、
溶液は、pH7に中和された。
Claims (15)
- 瞼と平行な結膜ひだ(LIPCOF)スケールによって測定される結膜弛緩症の重症度を低減させるための治療用点眼薬であって、グリセロール水溶液を含むことを特徴とする点眼薬。
- 前記溶液が、基本的に等張性であることを特徴とする請求項1に記載の点眼薬。
- 前記溶液が、pH7を有することを特徴とする請求項1又は2に記載の点眼薬。
- 前記点眼薬は、2mM未満の塩濃度を有することを特徴とする請求項1又は2に記載の点眼薬。
- 少なくとも10000ダルトンの分子量のポリマーをさらに含んでいることを特徴とする請求項1又は2に記載の点眼薬。
- 前記ポリマーの濃度が、前記溶液を所定の粘性とするように選択されることを特徴とする請求項5に記載の点眼薬。
- 前記ポリマーが、アニオン性であることを特徴とする請求項5に記載の点眼薬。
- 前記ポリマーが、ヒアルロン酸及びカルボマーからなる群から選択されることを特徴とする請求項7に記載の点眼薬。
- 薬学的に有効な量の薬理活性物質をさらに含んでいることを特徴とする請求項1又は2に記載の点眼薬。
- 前記薬理活性物質が、ジクロフェナクであることを特徴とする請求項9に記載の点眼薬。
- 安定剤、防腐剤、酸化防止剤、及び中和剤からなる群から選択される少なくとも1つの物質をさらに含んでいることを特徴とする請求項9に記載の点眼薬。
- 1日1回から5回の点眼薬の投与により、LIPCOFスケールによって測定される結膜弛緩症の症状の重度を低減させるために非外科的治療に使用されることを特徴とする請求項1から11のいずれか1項に記載の点眼薬。
- 前記治療が、1日3回の当該点眼薬の投与を含んでいることを特徴とする請求項12に記載の点眼薬。
- 前記投与の開始から6ヶ月以内に、結膜弛緩症の症状の重度における統計学的に有意な低減を生起するために該非外科的治療に使用されることを特徴とする請求項13に記載の点眼薬。
- 前記投与の開始から1ヶ月以内に、結膜弛緩症の症状の重度における統計学的に有意な低減を生起するために該非外科的治療に使用されることを特徴とする請求項13に記載の点眼薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL212725A IL212725A (en) | 2011-05-05 | 2011-05-05 | Glycerol Preparation for Non-surgical Conjunctivochalysis |
IL212725 | 2011-05-05 | ||
PCT/IL2012/000157 WO2012150583A1 (en) | 2011-05-05 | 2012-04-05 | Eye drops for treatment of conjunctivochalasis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014513118A JP2014513118A (ja) | 2014-05-29 |
JP5957517B2 true JP5957517B2 (ja) | 2016-07-27 |
Family
ID=44672108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508913A Active JP5957517B2 (ja) | 2011-05-05 | 2012-04-05 | 結膜弛緩症治療用の点眼薬 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8912166B2 (ja) |
EP (1) | EP2704747B1 (ja) |
JP (1) | JP5957517B2 (ja) |
KR (1) | KR101919017B1 (ja) |
CA (1) | CA2835013C (ja) |
DK (1) | DK2704747T3 (ja) |
ES (1) | ES2652024T3 (ja) |
HU (1) | HUE035185T2 (ja) |
IL (1) | IL212725A (ja) |
LT (1) | LT2704747T (ja) |
NO (1) | NO2704747T3 (ja) |
PL (1) | PL2704747T3 (ja) |
PT (1) | PT2704747T (ja) |
SI (1) | SI2704747T1 (ja) |
WO (1) | WO2012150583A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110891555B (zh) | 2017-03-05 | 2023-12-26 | 雷斯德沃克研究及发展有限公司 | 用于治疗非因感染引起的刺激的滴眼剂 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
SE9401109D0 (sv) * | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
WO2000001365A1 (en) * | 1998-06-30 | 2000-01-13 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Prolonged release ophthalmic compositions containing a fluoroquinolone |
PL356093A1 (en) * | 1999-11-09 | 2004-06-14 | Alcon Inc. | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
AU2003246241A1 (en) * | 2002-07-02 | 2004-01-23 | Wakamoto Pharmaceutical Co., Ltd. | Remedy or preventive for keratoconjunctival epithelial cell injury |
JP2004051593A (ja) * | 2002-07-23 | 2004-02-19 | Nippon Tenganyaku Kenkyusho:Kk | 低刺激性消炎点眼薬液 |
CN1488404A (zh) * | 2003-06-19 | 2004-04-14 | 刘继东 | 眼用制剂中玻璃酸钠的复合应用 |
WO2005067892A1 (en) * | 2004-01-10 | 2005-07-28 | Biolipid, Inc. | Lipid compositions and methods of use |
US20090214676A1 (en) * | 2005-04-30 | 2009-08-27 | Tissuetech, Inc. | Method for treating ocular demodex |
IL168603A (en) * | 2005-05-16 | 2011-05-31 | Resdevco Res And Dev Co | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
US20070212420A1 (en) * | 2006-03-10 | 2007-09-13 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
EP2078527A4 (en) * | 2006-10-12 | 2011-12-21 | Kyorin Seiyaku Kk | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION |
US20100086512A1 (en) * | 2008-10-02 | 2010-04-08 | Rolf Schaefer | Mucomimetic compositions and uses therefore |
CN101940701A (zh) * | 2010-10-11 | 2011-01-12 | 周安忠 | 一种芦荟眼膏及制备方法 |
-
2011
- 2011-05-05 IL IL212725A patent/IL212725A/en active IP Right Grant
-
2012
- 2012-04-05 PT PT127216166T patent/PT2704747T/pt unknown
- 2012-04-05 JP JP2014508913A patent/JP5957517B2/ja active Active
- 2012-04-05 ES ES12721616.6T patent/ES2652024T3/es active Active
- 2012-04-05 EP EP12721616.6A patent/EP2704747B1/en active Active
- 2012-04-05 HU HUE12721616A patent/HUE035185T2/hu unknown
- 2012-04-05 DK DK12721616.6T patent/DK2704747T3/en active
- 2012-04-05 SI SI201231128T patent/SI2704747T1/en unknown
- 2012-04-05 WO PCT/IL2012/000157 patent/WO2012150583A1/en active Application Filing
- 2012-04-05 LT LTEP12721616.6T patent/LT2704747T/lt unknown
- 2012-04-05 KR KR1020137032206A patent/KR101919017B1/ko active IP Right Grant
- 2012-04-05 CA CA2835013A patent/CA2835013C/en active Active
- 2012-04-05 PL PL12721616T patent/PL2704747T3/pl unknown
- 2012-04-05 NO NO12721616A patent/NO2704747T3/no unknown
-
2013
- 2013-11-05 US US14/071,934 patent/US8912166B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
LT2704747T (lt) | 2018-01-10 |
IL212725A (en) | 2016-06-30 |
DK2704747T3 (en) | 2018-01-02 |
US20140057983A1 (en) | 2014-02-27 |
IL212725A0 (en) | 2011-07-31 |
JP2014513118A (ja) | 2014-05-29 |
HUE035185T2 (hu) | 2018-05-02 |
SI2704747T1 (en) | 2018-01-31 |
KR101919017B1 (ko) | 2018-11-16 |
NO2704747T3 (ja) | 2018-02-10 |
EP2704747A1 (en) | 2014-03-12 |
CA2835013C (en) | 2019-02-19 |
EP2704747B1 (en) | 2017-09-13 |
US8912166B2 (en) | 2014-12-16 |
CA2835013A1 (en) | 2012-11-08 |
WO2012150583A1 (en) | 2012-11-08 |
PT2704747T (pt) | 2017-12-18 |
ES2652024T3 (es) | 2018-01-31 |
KR20140033077A (ko) | 2014-03-17 |
PL2704747T3 (pl) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6876079B2 (ja) | ヒアルロン酸ナトリウムとカルボキシメチルセルロースを含む人工涙液 | |
TWI463978B (zh) | Ophthalmic composition | |
WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
JP2005513106A (ja) | ヘパリンを保有する眼薬剤 | |
JP2023168547A (ja) | 眼科組成物 | |
WO2018074421A1 (ja) | 眼科用剤及び眼科用薬 | |
EP2068821A2 (en) | Ophthalmic pharmaceutical compositions and uses thereof | |
JP5957517B2 (ja) | 結膜弛緩症治療用の点眼薬 | |
KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
RU2670100C2 (ru) | Офтальмическая композиция для цвиттерионных мягких контактных линз | |
KR100963611B1 (ko) | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 | |
RU2677665C2 (ru) | Офтальмическая композиция для анионных мягких контактных линз | |
WO2020138135A1 (ja) | 眼科用組成物 | |
TWI805705B (zh) | 選擇性syk抑制劑之使用方法及醫藥組合物 | |
WO2007023877A1 (ja) | 角膜疾患治療剤 | |
RU2669558C2 (ru) | Офтальмологическая композиция для цвиттерионных мягких контактных линз | |
JP2024524590A (ja) | ドライアイを治療する薬物の製造におけるロキソプロフェンナトリウムの使用 | |
JP2023180710A (ja) | 視覚改善剤 | |
EA018202B1 (ru) | Офтальмологический гель и способ его приготовления |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140107 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20131129 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160620 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5957517 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |